SCHEMBL5315895

SCHEMBL5315895

Nc1nc(-c2ccccc2)cc2ncnn12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.54
ALDH1A1 P00352 8/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
HPGD P15428 3/20 0.49
POLB P06746 1/20 0.49
ADORA2A P29274 3/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
EGLN2 Q96KS0 1/20 0.47
ADORA1 P30542 2/20 0.47
MAPT P10636 2/20 0.46
PKM P14618 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 2/20 0.44
GLA P06280 1/20 0.44
ASIC3 Q9UHC3 1/20 0.43
CHEK1 O14757 1/20 0.43
CCNA2 P20248 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29781538 0.84 KDM4E (0.52) KDM4EALDH1A1SMN1; SMN2HPGDMAPK1
SCHEMBL5314326 0.75 SMN1; SMN2 (0.45) KDM4EALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL29781504 0.72 CSNK1A1 (0.38) HPGDADORA2AEGLN2ADORA1
SCHEMBL21731043 0.72 EGLN2 (0.38) EGLN2
SCHEMBL23169281 0.69 ADORA2A (0.53) KDM4EALDH1A1SMN1; SMN2HPGDADORA2A
SCHEMBL21731264 0.69 TP53 (0.55) KDM4EALDH1A1SMN1; SMN2HPGDADORA2A
SCHEMBL21731243 0.69 ADORA2A (0.53) KDM4EALDH1A1SMN1; SMN2HPGDADORA2A
SCHEMBL9823734 0.69 KDM4E (0.69) KDM4EALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL5146982 0.69 KDM4E (0.69) KDM4EALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL10460795 0.68 EGLN2 (0.44) KDM4EALDH1A1SMN1; SMN2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3611174-B1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR MEDSHINE DISCOVERY INC (CN) 2022-06-08 EP disclosed
US-11117899-B2 [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor MEDSHINE DISCOVERY INC. (CN) 2021-09-14 US disclosed
US-11066411-B2 2021-07-20 US disclosed
US-20200131184-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR MEDSHINE DISCOVERY INC. (CN) 2020-04-30 US disclosed
EP-3611174-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR Medshine Discovery Inc. (CN) 2020-02-19 EP disclosed
EP-1765825-A1 CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES AMGEN INC. (US) 2007-03-28 EP disclosed
WO-2006004702-A1 CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES AMGEN INC. (US) 2006-01-12 WO disclosed
US-20050288502-A1 Substituted heterocyclic compounds and methods of use AMGEN, INC. 2005-12-29 US disclosed
EP-0374914-B1 Diol metabolites of 7-phenyl-1,2,4-triazolo[1,5-c]-pyrimidines-5-amines SEARLE & CO (US) 1994-04-20 EP disclosed
EP-0374914-B1 Diol metabolites of 7-phenyl-1,2,4-triazolo[1,5-c]-pyrimidines-5-amines SEARLE & CO (US) 1994-04-20 EP disclosed
EP-0374914-A1 Diol metabolites of 7-phenyl-1,2,4-triazolo[1,5-c]-pyrimidines-5-amines G.D. Searle & Co. (US) 1990-06-27 EP disclosed
EP-0374914-A1 Diol metabolites of 7-phenyl-1,2,4-triazolo[1,5-c]-pyrimidines-5-amines G.D. Searle & Co. (US) 1990-06-27 EP disclosed
US-4866063-A Diol metabolites of 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines G. D. SEARLE & CO. (US) 1989-09-12 US disclosed
EP-0129247-A1 8-Substituted 7-phenyl-1,2,4-triazolo [2,3-c] pyrimidines-5-amines and amides G.D. Searle & Co. (US) 1984-12-27 EP disclosed
US-4483987-A 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides G. D. SEARLE & CO. (US) 1984-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117899-B2 [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor ADORA2A, ADORA1, ADORA3 KDM4E 3980/4885ALDH1A1 505/4885SMN1; SMN2 2261/4885
US-20050288502-A1 Substituted heterocyclic compounds and methods of use MYLK2, IAPP, MAPT KDM4E 3908/4885ALDH1A1 3162/4885SMN1; SMN2 13/4885
US-11066411-B2 ADORA2A, ADORA1, ADORA2B KDM4E 4570/4885ALDH1A1 494/4885SMN1; SMN2 810/4885
US-20200131184-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR ADORA2A, ADORA1, ADORA3 KDM4E 3980/4885ALDH1A1 505/4885SMN1; SMN2 2261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.